Profusa, Inc. — Filing Summary
Filing identity: The supplied 10-Q is for NorthView Acquisition Corp. (a SPAC), not Profusa, Inc. It covers the quarter ended September 30, 2022 and was filed November 10, 2022. It reports no Profusa operating results; the merger agreement with Profusa was signed after quarter-end.
Business context and reporting period
NorthView was formed to pursue a business combination, with a stated focus on healthcare innovation. As of September 30, 2022, it had not selected a target and had no operating revenue. On November 7, 2022, it entered into a merger agreement with Profusa, Inc.; the transaction remained subject to customary conditions, including minimum available cash and shareholder approvals.
Financial results and liquidity
- Revenue and operations: No operating revenue. Formation and operating costs were $404,425 for Q3 2022 and $863,546 for the first nine months of 2022.
- Net income: $1.76 million for Q3 and $6.69 million for the first nine months of 2022, compared with no Q3 2021 income and a $338 inception-period loss through September 30, 2021. 2022 income primarily reflected non-operating trust interest and gains from lower warrant fair values, not operating performance.
- Other income: Q3 trust interest was $1.14 million and the warrant fair-value gain was $1.07 million. Nine-month figures were $1.37 million and $6.25 million, respectively.
- Cash flow: Operating activities used $401,841 in the first nine months of 2022. Cash outside the trust account declined from $741,228 at year-end 2021 to $372,871 at September 30, 2022.
- Assets and liquidity: Total assets were $193.79 million, including $193.02 million held in trust. Management reported approximately $0.5 million of working capital.
- Debt and obligations: No long-term debt, lease obligations, or working-capital loans were reported. Current liabilities were $400,282; warrant liabilities were $969,125. Redeemable public shares were recorded outside permanent equity at $192.80 million.
- Margins: Not meaningful because the company had no operating revenue.
Material changes versus comparable periods
Compared with the 2021 inception-period results, 2022 reported substantial net income, but the change was driven mainly by trust interest and warrant remeasurement. Warrant liabilities fell from $7.22 million at December 31, 2021 to $969,125 at September 30, 2022, producing a reported nine-month gain of $6.25 million. Trust assets increased from $191.65 million to $193.02 million. The filing does not present a comparable full-year operating business because NorthView remained a SPAC.
Outlook, risks, and unusual items
- NorthView had until March 22, 2023 to complete a business combination, with a possible extension of up to six months. Management said completion by the deadline was uncertain and identified substantial doubt about going concern if the company had to liquidate.
- The November 7 Profusa merger agreement valued Profusa at a pre-transaction equity value of $155 million, using an assumed NorthView share value of $10. Profusa stockholders could receive up to 3.875 million additional shares based on specified stock-price and revenue milestones. Completion was not assured.
- The filing disclosed a potential 1% federal excise tax on certain stock repurchases after December 31, 2022, which could reduce cash available for a transaction.
- Management noted that COVID-19 and the Russia-Ukraine war could adversely affect the company or its target search, but the specific impact was not determinable.
- NorthView’s disclosed earnings are sensitive to warrant fair-value estimates and market prices. The filing reported no legal proceedings and no material changes to previously disclosed risk factors other than the excise-tax risk.
- Disclosure controls and procedures were assessed as effective as of September 30, 2022; no material quarterly change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the filing entity and reporting scope: this is NorthView’s 10-Q, not Profusa’s financial statements.
- Review the merger agreement’s minimum-cash condition, approvals, financing needs, and subsequent amendments or outcome.
- Check NorthView’s available cash outside the trust, trust balance, redemptions, and any sponsor extension deposits or loans.
- Assess the effect of warrant remeasurement and potential excise tax on reported earnings and transaction cash.
- Verify the merger consideration and conditions for the potential earnout shares.